Prognostic value of P53 aberrations in diffuse large B-cell lymphoma.
- Author:
Jing-Tao LU
1
;
Ling CEN
;
Min ZHOU
Author Information
1. Department of Hematology and Oncology, Nanjing Medical University, Changzhou, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Case-Control Studies;
Female;
Gene Deletion;
Genes, p53;
Humans;
Lymphoma, Large B-Cell, Diffuse;
diagnosis;
genetics;
pathology;
Male;
Middle Aged;
Prognosis;
Tumor Suppressor Protein p53;
genetics
- From:
Journal of Experimental Hematology
2012;20(1):100-102
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to analyze the P53 aberrations in diffuse large B-cell lymphoma (DLBCL) and its prognostic value. Using fluorescence in situ hybridization (FISH), the P53 gene was detected in paraffin-embedded tonsil tissues from 50 cases of DLBCL, while all the peripheral blood of patients was collected for detecting P53 protein in serum by using enzyme-linked immunosorbent assay (ELISA). The relationships between P53 gene and protein expression and the prognosis of patients with DLBCL were analyzed. The results showed that 21 out of 50 cases had P53 gene deletion, serum P53 protein content was (176.25 ± 61.25) pg/ml, which was higher than that in normal controls. The Cox model likelihood ratio test found that abnormal P53 could be used as independent prognostic factor in DLBCL patients. The risk of death in patients with P53 gene deletion were more than that in patients with P53 gene normal. The patients with histology P53 gene deletion detected by FISH also had relatively high level of mutant P53 protein in serum. It is concluded that P53 aberrations in patients with DLBCL can be used as an independent prognostic factor, the early detection of P53 in DLBCL patients helps to determine their prognosis accurately.
